|
|
CALGB ACTIVE PROTOCOLS: |
| NOTICE: The
following is a listing of CALGB active protocols that contain pathology
components. This is to be used as a reference and should not replace the
required material contained withing the protocol. |
|
|
BREAST: |
- 40101: CA(4 vs 6 cycles) vs Taxol(12 v 18 wks) in Node - Breast Ca
- 40105: Novel Therapeutic Agents in Br Ca: Celebrex
- 49801: Wide Local Excis +/- RT for Good Risk DCIS (R9804)
- 49907: Adj Chemo w/AC or CMF vs Capecitabine in Wm 65+
- 49909: AC->weekly T +/- Herceptin in Her2+Node+ (N9831)
- CTSU NCIC MA-27 exe.vs.ana.+/-celeco:PM w/ER-PR+ br ca
- CTSU IBCSG 24-02 SOFT Tam+/-OFS vs OFS + Exemest
- CTSU IBCSG 25-02 TEXT OFS + Tam vs OFS + Exemest
- CTSU IBCSG 26-02 PERCHE Chemo,Tam,OFS.Exemest
|
CANCER IN THE ELDERLY: |
| |
CANCER CONTROL & HEALTH OUTCOMES: |
- 79805: Soy & Vas Symp Prev in Post-Menop BrCa w/Tam
- 79806: Prostate Cancer Prevention Using Dietary Soy Suppl (Limited Access)
|
CORRELATIVE SCIENCES FOR SOLID TUMORS: |
- 150007: Correl Sci in Neoadj Trials for Locally Adv Br Ca (Limited Access)
- 150105: STI571 Response Markers in GIST
- 150201: Laboratory Studies in Hormone Refractory PCa
- 159805: Lab Studies in Elderly Women w/Breast Ca
- 159806: erbB2 and Paclitaxel Chemotherapy
- 159905: Correl Studies of ErbB2/p53 in CALGB 9344
|
GASTROINTESTINAL: |
- 80101: Ph III Trial of Adj Chemo after res of Gastric Adeno Ca
- 80203: Irin/5-FU/Lv vs. oxal/5-FU/Lv ± C-225 for met col ca
- 89808: 5-FU/Mitomycin-C/RT v 5-FU/Cis/RT-Anal Ca (R9811)
|
GENITOURINARY: |
- 9687: Salvage Prostatectomy for RT Failure in Prostate Ca
- 90102: Cisplatin/Gem/Iressa for Adv Urothel Tract Ca
- 90104: Adj seq doublet AG-TP vs cis/gem for TCC of bladder
- 90202: Early vs delayed zoledronic acid to prevent SREs in CaP
- 90206: IFNA +/- bevacizumab in pts with advanced RCC
- 99809: External RT w/Brachytherapy for Unfav Localized PCa
- 99811: Neo-adj Pacl./Est/Carbo + Andgn. Abl. Prior to RT
- 99904: Adj. Androg. Suppr. w/wo Mitox/pred in PC (S9921)
|
LEUKEMIA: |
- 9710: APL: ATRA + Chemo +/- As2O3 Followed by ATRA +/- 6-MP/MTX
- 10001: ALL: Seq Chemo, STI571 & Transplant in Ph+ ALL
- 10002: ALL: Rituxan + Hi Intensity CTX in Burkitt Lymph/Leuk
- 10003: Cyclosporin in T Cell Large Gran Lymphocytic Leuk
- 10102: Phase I/II study of subq campath-1H in ALL
- 10105: PTK787/ZK 222584 in Myelodysplastic Syndrome
- 10201: AML: DNR and Ara-C ± G3139 in Prev. Untrtd Pts w/ AML
- 19808: AML: Induc Chemo +/- PSC833 Followed By Risk Adapt Intens
|
LEUKEMIA CORRELATIVE SCIENCES: |
- 9764: Genetic Changes in DA-NHL
|
LYMPHOMA: |
- 50002: Ph. II Trial of Thalidomide for Rel/Ref Low Grade NHL
- 50103: EPOCH-R for Prev. Untreated Aggress B-Cell NHL
- 50206: PS-341 in pts with relapsed or refractory HD
- 59903: Hi Dose Chemo/ASCT vs Conv Dose CHOP (S9704)
- 59909: Induction Chemo Followed by ASCT + Rituximab for Mantle Cell Lymphoma
|
MELANOMA: |
- 500103: High Dose IFN in St. T3-4 or N1 Melanoma (E1697)
- 500104: R115777 in Patients with Metastatic Malignant Melanoma
- 500105: Melastatin Exp Predict Risk Loc/Reg Mets Prim Melanoma
|
PET: |
| |
|
|
RESPIRATORY: |
- 30106: ZD1839 induction/concurrent tx for NSCLC(Limited Access)
- 30107: PTK787 in Pts. w/mesothelioma
- 30203: Eicosanoid pthwy modulator & chemo in adv NSCLC
|
TRANSPLANT: |
- 109901: Minimal Ablation & Cellular Immune Tx in CLL & NHL
|
